Dr Hafron on a Multidisciplinary Quality Initiative Designed to Mitigate the AEs of ADT in Prostate Cancer

“Many patients weren’t taking the medications that they were prescribed, and there was a meaningful number of patients that weren’t getting cardiovascular care. We identified significant gaps. The next phase of PC360 is to intervene in these [areas] and show that our interventions will make a difference and improve outcomes and quality of life for these patients.”

Jason Hafron, MD, the chief medical officer and medical director of clinical research at the Michigan Institute of Urology and a professor of urology at the William Beaumont School of Medicine at Oakland University, discussed a study that examined a multidisciplinary quality initiative designed to mitigate and reduce the adverse effects (AEs) of androgen deprivation therapy (ADT) in prostate cancer. 

To develop the initiative, The Prostate Cancer 360 (PC360) Working Group gathered a multidisciplinary panel of 14 experts in prostate cancer and ADT management who systematically identified gaps and challenges in the recognition and management of ADT-related AEs. They then developed structured, consensus-driven recommendations aimed at supporting proactive monitoring, risk mitigation, and prevention of ADT-associated complications across the care continuum of prostate cancer. The study, which Hafron presented in a poster during the 2026 American Urological Association (AUA) Annual Meeting, evaluated the implementation of the PC360 recommendations within participating practices.

Findings from the study showed that among enrolled patients (n = 270), 93% qualified for chronic care management and 7% qualified for principal care management, Hafron explained. The study also revealed notable gaps in care; some patients weren’t taking the medications that they were prescribed (7%), and there was a significant number of patients that weren’t getting cardiovascular care (15%), he added. Additionally, 31% of patients were found to not have received a DEXA scan, he noted. The next phase of the initiative is to address these gaps in order to improve outcomes and quality of life for patients, he concluded.